Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

NCT02532764
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
QR-010, Placebo
Drug
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 2, 2026, 7:01 AM EDT
Recruiting No phase listed Observational

Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis

NCT06560463
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Access to Dexcom G7 CGM Data
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

EASY: Extended Access to Sollpura Over Years

NCT02823964
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Jackson, Mississippi • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 2, 2026, 7:01 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

NCT02496780
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
novolog insulin, levemir insulin, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Not applicable Interventional

Pilot Study to Evaluate a Voice Journaling Application in Adolescents With Cystic Fibrosis

NCT05420844
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Kintsugi voice journaling application
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Not applicable Interventional Results available

Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis

NCT00706004
View directory record Official record
Conditions
Constipation, Cystic Fibrosis
Interventions
lubiprostone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

NCT00179998
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Recombinant Human DNase (Pulmozyme), Placebos
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 30 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 2, 2026, 7:01 AM EDT
Recruiting Phase 1 Interventional

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

NCT07275905
View directory record Official record
Conditions
Cystic Fibrosis (CF), Achromobacter Infection
Interventions
AchromoPhage
Biological
Lead sponsor
Ghady Haidar
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Diego, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Omadacycline in Cystic Fibrosis

NCT04460586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet [Nuzyra]
Drug
Lead sponsor
Paul Beringer
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 2, 2026, 7:01 AM EDT
Enrolling by invitation No phase listed Observational

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

NCT04930289
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions
LungGuard, BAROGuard
Device
Lead sponsor
Paragonix Technologies
Industry
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Rollover Study of VX-770 in Cystic Fibrosis Subjects

NCT01117012
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
36
States / cities
Birmingham, Alabama • Oakland, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

NCT00677365
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
MP-376, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
16 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

NCT00880100
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT12
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Years to 6 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
15
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1Phase 2 Interventional

Project 2 Airway Potential Hydrogen (pH) in Asthma

NCT03617718
View directory record Official record
Conditions
Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Interventions
Glycine Buffer
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

NCT06861413
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 2, 2026, 7:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glycemic Monitoring in Cystic Fibrosis

NCT02211235
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 25 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

NCT01840735
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
GS-5737, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

28 Day Repeat Dose in Cystic Fibrosis Patients

NCT00903201
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SB656933, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

NCT01515007
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 2, 2026, 7:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Airway Clearance System (K031876) Phase IV Device Efficacy

NCT03437811
View directory record Official record
Conditions
Cystic Fibrosis, Pulmonary
Interventions
Electro Flo Percussor, Model 5000
Device
Lead sponsor
Mack Biotech, Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects

NCT00928135
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Xylitol, Hypertonic saline
Drug
Lead sponsor
Joseph Zabner
Other
Eligibility
12 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)

NCT00082238
View directory record Official record
Conditions
Cystic Fibrosis, Diabetes Mellitus
Interventions
Stable isotopes
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 2, 2026, 7:01 AM EDT
Terminated No phase listed Observational

A Study to Investigate Cystic Fibrosis Pulmonary Exacerbations and the Lung Microbiome

NCT05088447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Up to 22 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 2, 2026, 7:01 AM EDT